Pelacarsen
- Generic Name
- Pelacarsen
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1637637-70-7
- Unique Ingredient Identifier
- LSO9H7UZ90
- Background
Pelacarsen is under investigation in clinical trial NCT03070782 (Phase 2 Study of ISIS 681257 (Akcea-apo(a)-lrx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease).
- Associated Conditions
- -
- Associated Therapies
- -
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05900141
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT05337878
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT05026996
- Locations
- 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02414594
- Locations
- 🇨🇦
Clinical Site, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath